{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:57:29Z","timestamp":1783180649435,"version":"3.54.6"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.omton.2026.201153","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:56:04Z","timestamp":1770944164000},"page":"201153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapy"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6539-5265","authenticated-orcid":false,"given":"Liliana","family":"Maruri-Avidal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajit","family":"Limsirichai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Gulizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-0174","authenticated-orcid":false,"given":"David H.","family":"Kirn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201153_bib1","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired Resistance to Immune Checkpoint Inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201153_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-022-02846-x","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages","volume":"23","author":"Dong","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.omton.2026.201153_bib3","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41392-023-01683-2","article-title":"Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.omton.2026.201153_bib4","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14712598.2020.1729351","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors","volume":"20","author":"Chiu","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.omton.2026.201153_bib5","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/mt.2015.109","article-title":"Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer","volume":"23","author":"Park","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201153_bib6","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201153_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10358","article-title":"Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans","volume":"477","author":"Breitbach","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201153_bib7","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.cgt.7700819","article-title":"Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU\/leucovorin","volume":"12","author":"Reid","year":"2005","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201153_bib8","first-page":"6070","article-title":"Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints","volume":"62","author":"Reid","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201153_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2001.19.2.289","article-title":"Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer","volume":"19","author":"Nemunaitis","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2026.201153_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/78638","article-title":"a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer","volume":"6","author":"Khuri","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201153_bib11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.omton.2026.201153_bib12","series-title":"Patients with Advanced Hepatocellular Carcinoma (HCC) without Prior Systemic Therapy","article-title":"Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF\/Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib","year":"2015"},{"key":"10.1016\/j.omton.2026.201153_bib13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1110\/ps.2460102","article-title":"Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity","volume":"11","author":"Kokoris","year":"2002","journal-title":"Protein Sci."},{"key":"10.1016\/j.omton.2026.201153_bib14","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1038\/sj.onc.1205280","article-title":"Ganciclovir-induced apoptosis in HSV-1 thymidine kinase expressing cells: critical role of DNA breaks, Bcl-2 decline and caspase-9 activation","volume":"21","author":"Tomicic","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.omton.2026.201153_bib17","doi-asserted-by":"crossref","first-page":"19273","DOI":"10.1074\/jbc.M600414200","article-title":"Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation","volume":"281","author":"Balzarini","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2026.201153_bib18","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1089\/hum.2009.042","article-title":"TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy","volume":"21","author":"Preuss","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omton.2026.201153_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070231","article-title":"Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency","volume":"10","author":"Ricordel","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omton.2026.201153_bib20","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-07-6515","article-title":"Enhancing poxvirus oncolytic effects through increased spread and immune evasion","volume":"68","author":"Kirn","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201153_bib15","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1073\/pnas.93.8.3525","article-title":"Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy","volume":"93","author":"Black","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201153_bib16","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/sj.gt.3300966","article-title":"Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant","volume":"6","author":"Kokoris","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/j.omton.2026.201153_bib21","series-title":"Recombinant Vaccinia Virus and Methods of Use Thereof","first-page":"134","author":"Kirn","year":"2020"},{"key":"10.1016\/j.omton.2026.201153_bib22","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1016\/j.vaccine.2007.09.023","article-title":"Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice","volume":"25","author":"Melamed","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2026.201153_bib23","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.omton.2026.201153_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/378636a0","article-title":"Actin-based motility of vaccinia virus","volume":"378","author":"Cudmore","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201153_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"key":"10.1016\/j.omton.2026.201153_bib26","first-page":"431","article-title":"Insertion sites for recombinant vaccinia virus construction: effects on expression of a foreign protein","volume":"81","author":"Coupar","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.omton.2026.201153_bib27","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1016\/j.vaccine.2016.05.012","article-title":"Improved safety of a replication-competent poxvirus-based HIV vaccine with the introduction of the HSV-TK\/GCV suicide gene system","volume":"34","author":"Zhang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.omton.2026.201153_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines8100426","article-title":"Engineering and Preclinical Evaluation of Western Reserve Oncolytic Vaccinia Virus Expressing A167Y Mutant Herpes Simplex Virus Thymidine Kinase","volume":"8","author":"Islam","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.omton.2026.201153_bib29","article-title":"Replication-inducible vaccinia virus vectors with enhanced safety in vivo","volume":"15","author":"O'Connell","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2026.201153_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.biortech.2012.01.054","article-title":"Biocatalyst development by directed evolution","volume":"115","author":"Wang","year":"2012","journal-title":"Bioresour. Technol."},{"key":"10.1016\/j.omton.2026.201153_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.sbi.2011.05.003","article-title":"Strategy and success for the directed evolution of enzymes","volume":"21","author":"Dalby","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.omton.2026.201153_bib32","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1038\/s41467-021-27397-z","article-title":"Directed evolution of and structural insights into antibody-mediated disruption of a stable receptor-ligand complex","volume":"12","author":"Pennington","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201153_bib33","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201153_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.cgt.7700075","article-title":"Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant","volume":"7","author":"Puhlmann","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omton.2026.201153_bib36","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1472-6807-6-22","article-title":"Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design","volume":"6","author":"El Omari","year":"2006","journal-title":"BMC Struct. Biol."},{"key":"10.1016\/j.omton.2026.201153_bib37","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibition: The Best of Both Worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.omton.2026.201153_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omton.2026.201153_bib39","first-page":"51","article-title":"Construction of recombinant vaccinia viruses using leporipoxvirus-catalyzed recombination and reactivation of orthopoxvirus DNA","volume":"269","author":"Yao","year":"2004","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2026.201153_bib40","doi-asserted-by":"crossref","first-page":"5.12.1","DOI":"10.1002\/cpps.34","article-title":"Preparation of Cell Cultures and Vaccinia Virus Stocks","volume":"89","author":"Cotter","year":"2017","journal-title":"Curr. Protoc. Protein Sci."},{"key":"10.1016\/j.omton.2026.201153_bib41","doi-asserted-by":"crossref","first-page":"16.17.1","DOI":"10.1002\/cpmb.32","article-title":"Generation of Recombinant Vaccinia Viruses","volume":"117","author":"Wyatt","year":"2017","journal-title":"Curr. Protoc. Mol. Biol."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926000299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T20:26:39Z","timestamp":1778271999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926000299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2950329926000299"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201153","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravenous oncolytic vaccinia expressing transgenes for enhanced safety, inhibition of shedding, imaging, and systemic cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201153"}}